Navigation Links
Oxford Nanopore Technologies announces advanced development of LamPORE, for rapid, highly scalable, low-cost COVID-19 detection

Oxford Nanopore Technologies is in advanced development of a new generation of end-to-end test (assay) for the detection of SARS-CoV-2, the virus that causes COVID-19.

The LamPORE assay is designed to be rapid, low cost, and scalable to cater to on-demand analysis of smaller sample numbers, to very large numbers of samples. Hardware and reagents sit outside current, squeezed supply chains for other molecular tests.

LamPORE is based on Oxford Nanopore’s DNA/RNA sequencing technology, in combination with a simple, sample-preparation method (loop-mediated isothermal amplification, plus Oxford Nanopore’s ‘rapid kit’). It seeks to understand whether a sample currently contains the SARS-CoV-2 virus (rather than detecting antibodies that may indicate a previous infection).

Since the first emergence of the virus, Oxford Nanopore’s rapid, portable sequencing technology has been used extensively for COVID-19 epidemiology and scientific research.

LamPORE is the first assay that the Company has developed in-house with intended use in diagnostic applications, subject to relevant authorisations that the Company is currently pursuing. Oxford Nanopore is planning to deploy LamPORE for COVID-19 in a regulated setting initially on GridION and soon after on the portable MinION Mk1C.

The LamPORE protocol will also be made openly available for research use on any Oxford Nanopore device.

Oxford Nanopore’s vision is to support wide efforts to identify, track, trace and isolate cases. LamPORE is designed to enable rapid detection of SARS-CoV-2, whether in a high-throughput centralised lab processing thousands of samples, or for on-demand analysis in decentralised locations, so that analysis can be performed in more community settings.
LamPORE is designed to enable:

  • Very high throughput, centralised lab-based analyses: for example, to support routine screening of workforces - whether on the frontline or to support a general return to work. This might include regular screening of healthcare workers/other public sector employees, or businesses’ employees, whether symptomatic or asymptomatic.
  • Near-community: Also designed to be deployable in decentralised environments, LamPORE opens up potential opportunities for rapid, local testing as restrictions are eased, for example in care homes, transport networks, businesses or other community settings. Decentralisation supports rapid turnaround of testing, which is important to enable rapid, precise isolation and therefore prevent onwards transmission of the virus.

The LamPORE method can also be used to analyse environmental samples to assess for the presence of the SARS-CoV-2 virus. This has the potential to be used for swabbing surfaces, or systems such as water treatment.
LamPORE does not rely on reagents used in traditional COVID-19 tests, which could ease pressure on current supply chains and expand access.

“This year we have gained extensive experience supporting customers using our sequencing technology for COVID-19 epidemiology, and we have also been directing our own powerful innovation and development engine at COVID-19,” said Dr Gordon Sanghera, CEO of Oxford Nanopore.

“We designed our first nanopore sequencing device to be used by any scientist, anywhere. Now, with LamPORE, we want to bring the accessibility and scalability of nanopore sequencing into the area of rapid testing,”

Oxford Nanopore is collaborating with scientists in multiple institutions for rapid optimisation and validation of the LamPORE method for SARS-CoV-2 detection.

Find out more:

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Oxford University Press to publish BioScience journal from 2014
2. Oxford University Press to publish Entomological Society of America publications in 2015
3. InSilico Medicine CEO to present at Oxford University
4. New NIH awards focus on nanopore technology for DNA sequencing
5. Nanopore opens new cellular doorway for drug transport
6. Nanopores control the inner ears ability to select sounds
7. Researchers use virus to reveal nanopore physics
8. NREL staff recognized for breakthrough technologies
9. Evonik Industries Selects OPX Biotechnologies for Joint Development of Bio-Based Chemicals
10. PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace
11. Join Leading Organizations at Biodetection Technologies 2013 in Alexandria, VA from June 18-19, 2013
Post Your Comments:
(Date:7/2/2020)... CITY, Calif. (PRWEB) , ... July 01, 2020 ... ... biotech company, presented its phase 1a findings of Neihulizumab, a biologic for the ... conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... for biopharmaceutical R&D, today announced that it has entered into a multi-year ... antibodies (Multiclonics®), to support their translational and clinical research strategy to discover ...
(Date:6/23/2020)... MILTON KEYNES, England (PRWEB) , ... June 23, ... ... operations in Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and ... rapid response project to support testing operations in the fight against the COVID-19 ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been ... webinar will cover the history of eSource, the reasons it did not take off ... wearables, to site source, the industry is moving towards capturing data electronically for clinical ...
(Date:7/22/2020)... , ... July 22, 2020 , ... Join experts from ... Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar on ... regulating body in China for drugs and medical devices. Specifically, for medical devices, the ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , ... and prevention of high-burden diseases, and Centric Consulting, a business and technology consulting ... utilize existing data in order to identify and prioritize patients for care. , ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Technology (MIT) has expanded the company’s exclusive license to include clinical applications ... point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast ...
Breaking Biology Technology: